Last reviewed · How we verify

Phenprocoumon, Ticagrelor, ASA

Medical University of Vienna · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Phenprocoumon, Ticagrelor, ASA is a Small molecule drug developed by Medical University of Vienna. It is currently FDA-approved.

Phenprocoumon, Ticagrelor, and ASA (Aspirin) are medications used to treat various conditions, including Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, and Antiphospholipid Syndrome. Ticagrelor specifically works as a small molecule negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor.

At a glance

Generic namePhenprocoumon, Ticagrelor, ASA
SponsorMedical University of Vienna
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Phenprocoumon, Ticagrelor, ASA

What is Phenprocoumon, Ticagrelor, ASA?

Phenprocoumon, Ticagrelor, ASA is a Small molecule drug developed by Medical University of Vienna.

Who makes Phenprocoumon, Ticagrelor, ASA?

Phenprocoumon, Ticagrelor, ASA is developed and marketed by Medical University of Vienna (see full Medical University of Vienna pipeline at /company/medical-university-of-vienna).

What development phase is Phenprocoumon, Ticagrelor, ASA in?

Phenprocoumon, Ticagrelor, ASA is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing